Zilretta (triamcinolone acetonide ER) / CSPC Pharma, Hong Kong Tainuo Pharma, Pacira - LARVOL DELTA

Comparative Efficacy of Triamcinolone versus Dexamethasone in Local Injection for Stenosing Tenosynovitis of the Metacarpophalangeal Joint: A Retrospective Cohort Study. (PubMed, Drug Des Devel Ther) - "However, the comparative efficacy of lipophilic sustained-release triamcinolone versus hydrophilic short-acting dexamethasone remains underexplored...In this retrospective matched cohort, triamcinolone was associated with superior 3-month efficacy and lower recurrence compared to dexamethasone. These findings are hypothesis-generating and warrant prospective dose-controlled confirmation."

Clinical • Journal • Retrospective data • Inflammation

CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) - P4 | N=150 | Active, not recruiting | Sponsor: The Cleveland Clinic | Trial completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Immunology • Orthopedics • Osteoarthritis • Rheumatology

TKACSI: Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (clinicaltrials.gov) - P2/3 | N=240 | Recruiting | Sponsor: Walter Reed National Military Medical Center | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027

Enrollment open • Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Rheumatology

ZILRETTA in Subjects With Shoulder Osteoarthritis (clinicaltrials.gov) - P3 | N=150 | Active, not recruiting | Sponsor: Pacira Pharmaceuticals, Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Aug 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: University of Kansas Medical Center | Trial completion date: Oct 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Diabetes • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 Diabetes. (PubMed, Ther Adv Musculoskelet Dis) - "● This plain language summary of publications outlines 2 publications based on separate analyses of a single study. The results of that single study may be different from results of other studies."

Journal • P2 data • Review • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) - P4 | N=150 | Active, not recruiting | Sponsor: The Cleveland Clinic | Enrolling by invitation ➔ Active, not recruiting | Trial primary completion date: Jan 2026 ➔ Aug 2026

Enrollment closed • Trial primary completion date • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis. (PubMed, Acta Pharm Sin B) - "The needle section contains PTP nanoparticles (NPs) loaded with triamcinolone acetonide (TA) and coated with a reactive oxygen species (ROS)-responsive layer, while the base section of the patch encapsulates sodium percarbonate (SPC) particles that serve as oxygen generators to facilitate deep penetration of the PTP NPs into inflammatory sites and improve PDT efficacy. Moreover, the PTP NPs enable sustained release of TA drug over 6 days, demonstrating potent anti-inflammatory activity. In an imiquimod-induced psoriatic mouse model, a single application of the S-PTP MN patch demonstrated superior therapeutic efficacy compared to the conventional topical TA cream, with significantly alleviated clinical symptoms, reduced epidermal thickness, and lowered inflammatory cytokine levels, highlighting the potential of the S-PTP MN patch as a clinically translatable strategy for effective psoriasis therapy."

Journal • Dermatology • Immunology • Inflammation • Psoriasis

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: Pacira Pharmaceuticals, Inc | N=32 ➔ 1 | Trial completion date: Apr 2026 ➔ Oct 2025 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2026 ➔ Oct 2025; Study was stopped due to business decision and lack of enrollment. There were no safety concerns.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Immunology • Osteoarthritis • Pain • Rheumatology

Development of a FU/TA ethosome-based polymeric nanocomposite film for sustained, non-invasive hypertrophic scar therapy: from bench to clinic. (PubMed, Int J Pharm) - "The current first-line treatment for hypertrophic scars (HS) involves multiple intralesional injections of 5-fluorouracil (5-Fu) and triamcinolone acetonide (TA), which can be extremely painful due to the dense nature of scar tissue and is often poorly tolerated by patients...Vancouver Scar Scale (VSS) assessments indicated notable improvements, including decreased scar height and enhanced skin pliability. These preliminary findings highlight the potential of FU/TA-EF as a promising, non-invasive therapeutic strategy for HS treatment."

Journal • Pain

FormulationLAI: A physiology-based machine learning framework for accelerated development of long-acting injectable formulations. (PubMed, J Control Release) - "Using the commercial poly (lactic-co-glycolic acid) (PLGA)-based injectable Zilretta® as a benchmark, PBPK/PD modeling was used to define target in vitro release profiles that maximize therapeutic exposure...The transformative computational framework could significantly reduce the formulation development time during the preclinical phase from the traditional 5-7 years to approximately 1-2 years. This framework redefines the formulation paradigm: from empirical "formulate-and-test" to predictive "compute-and-validate", and offers a scalable strategy for rational, efficient development of long-acting injectables."

Journal

CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) - P4 | N=150 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial primary completion date: Sep 2025 ➔ Jan 2026

Trial primary completion date • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

ZILRETTA in Subjects With Shoulder Osteoarthritis (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Pacira Pharmaceuticals, Inc | N=250 ➔ 150 | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Enrollment change • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Pacira Pharmaceuticals, Inc | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

TKACSI: Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (clinicaltrials.gov) - P2/3 | N=240 | Not yet recruiting | Sponsor: Walter Reed National Military Medical Center

New P2/3 trial • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Rheumatology

Analgesic effect of local anesthesia in total knee arthroplasty: protocol of a randomized controlled clinical trial. (PubMed, Int J Surg Protoc) - "This phase II randomized controlled trial evaluates a dual-optimization strategy combining anatomic mapping-guided periarticular cutaneous nerve (PCN) blockade with a sustained-release triamcinolone-ropivacaine formulation to address these limitations. In this single-center, assessor-blinded, 2 × 2 factorial design, 120 adults undergoing primary unilateral TKA were randomized to four intervention arms: Group 1: Conventional iPACK (interspace between the popliteal artery and posterior knee capsule) site + novel formulation (1% ropivacaine + 40 mg triamcinolone); Group 2: PCN block site + standard formulation (1% ropivacaine + 5 mg dexamethasone); Group 3: PCN block + novel formulation; Group 4: Control (iPACK + standard formulation)...Primary endpoints included: resting/movement-induced pain intensity (Visual Analog Scale) at 6, 24, and 48 h postoperatively, cumulative opioid consumption (morphine milligram equivalents), functional recovery metrics (knee flexion..."

Clinical • Journal • Anesthesia • Infectious Disease • Orthopedics • Pain

CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) - P4 | N=150 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Pacira Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

Preparation and In Vitro Characterization of Triamcinolone Acetonide-Loaded Lipid Liquid Crystal Nanocarriers for Ocular Delivery. (PubMed, Adv Pharm Bull) - "This study aimed to develop sustained-release triamcinolone acetonide (TA) formulations using lipid liquid crystals (LLCs) for ocular drug delivery and to characterize the designed formulations. PLM analysis revealed the presence of hexosomes and cubosomes, indicating that an increase in hexosomes contributed to a more uniform drug release from the formulations. Overall, the study findings suggest that liquid crystalline carriers can be a promising formulation for sustained ocular drug delivery of TA."

Journal • Preclinical

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: University of Kansas Medical Center | Trial completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Diabetes • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Pacira Pharmaceuticals, Inc

New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology

ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis (clinicaltrials.gov) - P1 | N=39 | Terminated | Sponsor: University of Virginia | Recruiting ➔ Terminated; Not able to find enough subjects

Trial termination

CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) - P4 | N=150 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial completion date: May 2025 ➔ Aug 2025 | Trial primary completion date: Mar 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Treatment Journey for Nonoperative Symptomatic Knee Osteoarthritis: Data from a New Real-World Registry. (PubMed, Surg Technol Int) - "Patients who received IA-TAER were more likely to repeat the same injection, with 73% repeating at least once and no adverse events were attributed to repeated injections. Approximately half of the patients have switched from the initial treatment offered during follow up, with the use of IA-TAER associated with higher rates of repeated treatment. Significance and Innovation 1. Our study used a newly developed real-world registry IGOR to characterize treatment progression for patients with symptomatic knee OA undergoing up to five rounds of nonoperative treatment. 2. Non-surgical interventions included cryoneurolysis, intra-articular injections of NSAIDs, hyaluronic acid injections, corticosteroid, or extended release steroid (triamcinolone) injections. 3. We found 73% of patients treated with intra-articular extended-release steroid injections repeated treatment at least once, relative to 60% by other treatments. 4. We found approximately half of patients switched from..."

Journal • Real-world evidence • Immunology • Osteoarthritis • Pain • Rheumatology

Improved Sleep Associated With Triamcinolone Acetonide Extended-Release Injections for Knee Osteoarthritis: Use of a New Real-World Registry. (PubMed, Arthroplast Today) - "Extended-release triamcinolone injections are associated with decreased sleep disturbance relative to other treatments, in both degree of improvement and proportion of patients. Further studies should examine the potential beneficial effects of IA-TA-ER on other aspects of health-related quality of life."

Journal • Real-world evidence • CNS Disorders • Immunology • Osteoarthritis • Pain • Rheumatology • Sleep Disorder